Non-opioid Pain Treatment Market Size, Trends, Share, Growth | Report 2022-2030
The global non-opioid pain treatment market was surpassed at USD 38.7 billion in 2021 and is expected to hit around USD 78.14 billion by 2030, growing at a CAGR of 8.12% from 2022 to 2030.
Report Highlights
The growth can be attributed to an increase in the prevalence of inflammatory diseases coupled with the robust product pipeline of novel non-opioid analgesics. According to the Centers for Disease Control and Prevention (CDC), around 32.5 million people are living with osteoarthritis condition in the U.S. In addition, according to the Spondylitis Association of America, about 3.2 million adult people in the U.S. have some form of Spondyloarthritis.
Initiatives are undertaken by government & nonprofit organizations to promote the usage of safer alternatives to opioids such as NSAIDs to address the increasing demand for pain relieving medicines. For instance, in February 2022, the U.S.FDA issued draft guidelines to provide recommendations to pharmaceutical companies for developing NSAIDs for the treatment of acute pain lasting for 30 days. This initiative was a part of the government’s “HHS Overdose Prevention Strategy” which focuses on the prevention, reduction, treatment, and recovery of patients from an opioid overdose. Such an initiative is projected to fuel demand for NSAID drugs over the forecast period.
Key market players are aggressively developing innovative techniques to meet the growing demand for NSAIDs for the management of pain. For instance, in June 2021, the University of Arizona developed oxytocin analogs for the treatment of patients suffering from. It is a bioavailable non-opioid pain relief product with the potential for inhaled administration. The development of such an innovative product is anticipated to drive non-opioid analgesics treatment market growth.
In September 2022, the U.S. FDA recommended avoiding non-opioid analgesics treatment in pregnancy at 20 weeks due to the high chances of kidney problems in unborn babies. Such initiatives from governments may limit the prescription of NSAIDs, thereby, restraining non-opioid pain treatment market growth.
Companies are adopting strategies such as new product development, launches, and partnerships to increase the penetration of non-opioid analgesic products. For instance, in March 2022, Vertex Pharmaceuticals announced positive results of its phase 2 clinical trial non-opioid pill that showed a significant reduction in post-operative acute pain. Successful completion of trial and subsequent approval of products is anticipated to drive non-opioid analgesics treatment market growth during the forecast period.
The market is highly competitive and the competition in the market is expected to be high during the forecast period due to the presence of a large number of players. Key companies manufacturing generic NSAID products include GSK plc., Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Johnson & Johnson Services, Inc., amongst others.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 38.7 billion |
| Revenue Forecast by 2030 | USD 78.14 billion |
| Growth rate from 2022 to 2030 | CAGR of 8.12% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Drug class, pain type, route of administration, distribution channel, region |
| Companies Covered |
Novartis AG; Teva Pharmaceutical Industries Limited; Dr. Reddy’s Laboratories Ltd; Sun Pharmaceutical Industries Ltd; GSK plc.; Pfizer Inc.; Perrigo Company plc; LNK International, Inc.; Cipla Inc.; Johnson & Johnson Services, Inc.; Pacira Pharmaceuticals, Inc.; Pierrel |
Drug Class Insights
The nonsteroidal anti-inflammatory drugs (NSAIDs) segment dominated the industry and accounted for a revenue share of 57.31% in 2021. The segment is anticipated to maintain its dominance during the forecast period owing to the wide availability of effective NSAID medications with low costs and safer alternatives to opioids for treatment. Some of the NSAIDs that are globally used include Cambia, Cataflam, Dyloject, Zipsor, Zorvolex, Advil, Motrin, and Aleve, among others.
In addition, advancement in drug formulation and increased penetration of new products in the market contributes to the continued dominance over the forecast period. For instance, in March 2020, the U.S. Food and Drug Administration (FDA) approved Advil Dual Action for the treatment of patients with dental pain. This drug was a combination of acetaminophen and ibuprofen to be available over the counter (OTC) for dental patients in the U.S.
The others segment is anticipated to witness the fastest growth during the forecast period owing to the wide availability of anticonvulsants and antimigraine drugs coupled with the presence of potential pipeline candidates to address the unmet needs for non-opioids-based therapies. For instance, Grünenthal is currently engaged in the development of late staged pipeline products such as RTX (resiniferatoxin), MPC-06-ID, and Qutenza (label expansion) for the treatment of pain associated with osteoarthritis of the knee, chronic low back pain, and post-surgical neuropathic pain respectively.
Pain Type Insights
The chronic pain segment dominated with a revenue share of 37.68% in 2021 owing to the increasing prevalence of chronic pain such as neuropathic pain and pain associated with inflammatory conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and others coupled with increased demand for non-opioid analgesic drugs. According to the National Library of Medicine, approximately 7% of the world’s population suffers from neuropathic pain. Thus, the increasing prevalence of diseases is anticipated to increase the prescription rate for NSAID medicines.
The others segment is estimated to witness lucrative growth during the forecast period. The growth of the segment can be attributed due to increasing unintentional or accidental injuries and acute pain. According to the CDC, around 24.8 million visited physician’s offices due to accidental injuries. Hence, increasing accidental injuries subsequently increases demand for pain relief products such as non-opioid analgesics for their pain treatment, thereby, driving the market growth.
Route Of Administration Insights
The oral segment dominated the non-opioid analgesics market and accounted for a revenue share of 47.91% in 2021 owing to the approval and launch of new oral NSAIDs for pain management. Key oral non-opioid analgesics drug prescribed by physicians to their patients for pain management includes Celebrex (celecoxib), Cambia, Cataflam, Dyloject, Zipsor, and Zorvolex (diclofenac potassium), Anaprox, Anaprox Ds, Ec-Naprosyn, Naprosyn, Naprelan, and Treximet (naproxen sodium), Lodine (etodolac), Nalfon (fenoprofen), Motrin & Advil (ibuprofen), and Daypro (oxaprozin), among others. Advil is available in tablet formulation and administered orally to relieve pain from various conditions such as muscle aches, dental pain, headache, and menstrual cramps.
The injectable segment is estimated to exhibit the fastest growth rate of 9.22% over the forecast period, owing to the factors such as technological advancements in drug delivery and the commercialization of novel IV products, and the increasing usage of local anesthetic products for surgical procedures. For instance, in February 2021, the U.S. FDA approved the first and only acetaminophen injection developed by B Braun Medical for the treatment of pain conditions caused by various diseases.
Distribution Channel Insights
The retail pharmacy segment dominated the non-opioid pain treatment market and accounted for a revenue share of 53.98% in 2021, owing to the wide availability of non-opioid analgesic drugs and easy accessibility to medicines for patients. The major retail pharmacies which provide non-opioid analgesics are Walgreens Boots Alliance, Inc., CVS Health, Ahold Delhaize, Rite Aid Corp., and Albertsons Companies, Inc. According to the Consumer Healthcare Products Association (CHPA) the sales of OTC analgesics external & internal reached USD 1,286 million & USD 4,640 million respectively in 2021.
The hospital pharmacy segment is the second largest revenue-generating segment in 2021. This can be attributed due to the widespread use of non-opioid analgesics for the treatment of hospitalized patients. In addition, the rise in the number of hospitals that perform various ambulatory surgeries for the treatment of various diseases would escalate the growth of the segment during the forecast period.
Regional Insights
North America dominated the non-opioid pain treatment industry and accounted for a revenue share of 38.63% in 2021. This dominance can be attributed to the high demand for NSAIDs, proactive government measures for limiting opioid use, improvements in healthcare infrastructure, and the presence of major players. Favorable government initiatives and reimbursement policies are likely to drive market growth.
Asia Pacific region is estimated to witness the fastest growth rate during the forecast period. The high growth rate can be attributed to initiatives undertaken by key players to develop and commercialize non-opioid analgesics in the region. In July 2022, NeuroFront Therapeutics and Novaremed AG announced an exclusive licensing and collaboration agreement for the commercialization of NRD.E1 to treat patients with neuropathic pain in Singapore and Greater China.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Non-opioid Pain Treatment Market
5.1. COVID-19 Landscape: Non-opioid Pain Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Non-opioid Pain Treatment Market, By Drug Class
8.1. Non-opioid Pain Treatment Market, by Drug Class, 2022-2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Acetaminophen
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Local Anesthetics
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Non-opioid Pain Treatment Market, By Pain Type
9.1. Non-opioid Pain Treatment Market, by Pain Type, 2022-2030
9.1.1. Chronic Pain
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Post-operative Pain
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Cancer Pain
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Non-opioid Pain Treatment Market, By Route of Administration
10.1. Non-opioid Pain Treatment Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Injectable
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Topical
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Non-opioid Pain Treatment Market, By Distribution Channel
11.1. Non-opioid Pain Treatment Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Others
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Non-opioid Pain Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Pain Type (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Novartis AG
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Teva Pharmaceutical Industries Limited
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dr. Reddy’s Laboratories Ltd
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sun Pharmaceutical Industries Ltd
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. GSK plc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Pfizer Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Perrigo Company plc,
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. LNK International, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Cipla Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Services, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers